Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

GC Biopharma stock

006280.KS
KR7006280002

Price

130,100.00
Today +/-
-0.54
Today %
-0.61 %
P

GC Biopharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the GC Biopharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the GC Biopharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the GC Biopharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze GC Biopharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

GC Biopharma Stock Price History

DateGC Biopharma Price
11/19/2024130,100.00 undefined
11/18/2024130,900.00 undefined
11/15/2024138,600.00 undefined
11/14/2024139,300.00 undefined
11/13/2024140,200.00 undefined
11/12/2024146,800.00 undefined
11/11/2024154,000.00 undefined
11/8/2024154,200.00 undefined
11/7/2024154,000.00 undefined
11/6/2024163,100.00 undefined
11/5/2024163,100.00 undefined
11/4/2024162,500.00 undefined
11/1/2024152,200.00 undefined
10/31/2024162,400.00 undefined
10/30/2024159,500.00 undefined
10/29/2024159,000.00 undefined
10/28/2024163,000.00 undefined
10/25/2024162,600.00 undefined
10/24/2024166,100.00 undefined
10/23/2024165,500.00 undefined
10/22/2024169,700.00 undefined

GC Biopharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into GC Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GC Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GC Biopharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of GC Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into GC Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing GC Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GC Biopharma’s growth potential.

GC Biopharma Revenue, EBIT and net profit per share

DateGC Biopharma RevenueGC Biopharma EBITGC Biopharma Net Income
2026e2.06 T undefined123.5 B undefined68.46 B undefined
2025e1.89 T undefined99.43 B undefined43.73 B undefined
2024e1.75 T undefined65.42 B undefined7.79 B undefined
20231.63 T undefined34.44 B undefined-26.63 B undefined
20221.71 T undefined81.26 B undefined65.45 B undefined
20211.54 T undefined73.66 B undefined123.21 B undefined
20201.5 T undefined50.25 B undefined81.05 B undefined
20191.36 T undefined41.68 B undefined-3.64 B undefined
20181.33 T undefined50.15 B undefined34.43 B undefined
20171.29 T undefined90.3 B undefined53.25 B undefined
20161.2 T undefined78.45 B undefined62.97 B undefined
20151.05 T undefined91.68 B undefined94.97 B undefined
2014975.33 B undefined96.97 B undefined83.95 B undefined
2013888.17 B undefined78.81 B undefined70.07 B undefined
2012811.77 B undefined74.36 B undefined53.64 B undefined
2011767.91 B undefined85.39 B undefined55.37 B undefined
2010793.05 B undefined153.05 B undefined113.69 B undefined
2009643.21 B undefined119.39 B undefined80.52 B undefined
2008516.1 B undefined67.93 B undefined48.87 B undefined
2007442.3 B undefined58.45 B undefined44.36 B undefined
2006405.12 B undefined54.86 B undefined34.79 B undefined
2005372.37 B undefined33.96 B undefined29.13 B undefined
2004141.98 B undefined5.02 B undefined6.78 B undefined

GC Biopharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (T)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.040.040.050.060.050.10.140.370.410.440.520.640.790.770.810.890.981.051.21.291.331.361.51.541.711.631.751.892.06
-21.2120.299.24-17.49125.4736.04162.278.809.1816.6924.6323.30-3.175.719.419.817.4314.327.513.651.6710.832.2411.28-4.957.847.958.66
26.9035.7439.0132.7233.6033.0433.2036.0940.6440.7939.5741.9440.6033.7131.2430.9531.8432.3529.3928.4825.9127.4229.2933.8534.0029.7927.6325.5923.55
9.4815.2620.0318.3615.5534.4847.14134.39164.65180.4204.24269.75321.94258.86253.58274.89310.5339352.08366.8345.87372.17440.63520.59581.8484.63000
-49.16-87.07-8.4730.414.847.26.7829.1334.7944.3648.8780.52113.6955.3753.6470.0783.9594.9762.9753.2534.43-3.6481.05123.2165.45-26.637.7943.7368.46
-77.11-90.27-459.07-84.0948.90-5.86329.5619.4327.4910.1864.7641.19-51.30-3.1130.6219.8113.13-33.69-15.44-35.34-110.57-2,327.8452.02-46.88-140.69-129.25461.3156.57
-----------------------------
-----------------------------
100097699101010101111111212121111111111.4111.4111.41000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The GC Biopharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the GC Biopharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (T)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (T)TOTAL ASSETS (T)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (T)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (T)TOTAL CAPITAL (T)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
2.082.241.8349.9630.435.5618.6215.9314.9112.5411.765.66135.9685.2229.3347.0792.06113.32117.2171.25106.74141.53255.5202.94112.3155.51
27.9424.5529.0823.756.3724.6861.2885105.55121.47160.02167.56155.6218.45217.8253.71253.45286.99341.36359.1379.72388.5402.12413.82394.46437.64
81.760.830.050.050.131.464.41.331.521.841.061.281.030.971.033.522.621.643.779.1111.6616.7220.7110.1715.0413.37
6.976.626.656.566.8614.972.6978.2386.8482.44112.47211.68195.33198.11210.73250.02298.4324.73320.75381.27386.93406.56437.07454.98442.41516.25
0.230.270.180.40.250.371.043.58.094.6719.2315.875.545.532.616.6316.3616.7818.35.818.388.4816.6513.7216.2316.39
0.120.030.040.080.040.050.160.180.220.220.30.460.490.510.460.560.660.740.80.930.890.961.131.10.981.04
34.8535.2532.7431.4424.5431.3260.1171.0798.62148.3195.76196.13221.02251.61300.8368.13408.86500.4554.03552559.66718.73751.1899.85930.82952.7
8.184.7520.615.955.483.2515.2729.8733.9738.9127.5434.1626.7963.69146.28122.9195.4693.24101.88111.36135.88129.56114.03130.69230.34223.3
0000000000000000000.050.050.050.050.280.284.782.78
0.090.080.180.20.110.824.46.337.179.314.213.4211.4519.5327.332.3942.0441.8455.7772.7890.6692.9599.5134.93169.09195.41
000002.461.461.10.730009.6511.211.0912.5312.5918.3817.8515.1310.1810.0710.07142.48142.48142.48
4.853.923.783.60.33.2311.524.395.276.187.47.276.446.047.417.368.5117.819.6725.7233.5546.1644.3958.367.687.5
0.050.040.060.050.030.040.090.110.150.20.240.250.280.350.490.540.670.670.750.780.8311.021.371.551.6
0.170.080.10.130.070.090.250.30.360.430.550.710.770.860.951.11.331.421.551.71.721.962.152.462.532.64
                                                   
16.693.343.3427.2724.0924.0945.0645.0645.0645.0645.0645.064950.6650.6658.4358.4358.4358.4358.4358.4358.4358.4358.4358.4358.43
16.7130.0530.0529.9431.6424.2879.0375.1977.4882.8784.1490.94165.13203.2203.26302.06304.72299.52312.74312.57315.39324.17325.22374.03381.74381.81
-46.59-49.11-57.58-27.17-22.33-14.28-8.2626.7357.0797.41137.44209.11311.89348.2385.02445.88513.43595.45637.24677.47701.79679.53757.28867.35903.47872.99
0000001.551.51.231.181.3211.7911.6411.4911.3311.311.7211.7911.7911.7911.9312.0512.1811.4911.4611.65
5.862.6818.54140.50.081.33.758.3614.213.842.474.265.1622.1219.3418.285.528.5715.667.7710.261.11-0.838.7311.05
-0.01-0.01-0.010.040.030.030.120.150.190.240.270.360.540.620.670.840.910.971.031.081.11.081.151.311.361.34
3.171.953.984.35.078.2527.7743.1836.7938.4748.49101.1454.9989.575.84100.22120.39131.37118.27158.8144.93139.27134.79119.54121.27143.82
0.121.332.620.062.625.249.1712.4913.7213.7419.3523.9526.8924.2824.1230.8432.8837.7540.6446.6151.5374.3988.7794.77106.539.7
3.871.862.6845.774.261.5811.398.8927.4248.4728.4293.0944.7148.6250.0650.2258.6579.9345.0948.6541.5847.463.97103.32113.98152.81
00000.2726.0873.7865.1648.011983.65.8471.9228.4673.9527.71122.4658.6915.35.592.0641.13203.2101.1182315.45
3.144.575.664.881.864.7914.03014101545.18000000840.463.3999.2398.68134.1617217.15
10.39.7214.9355.0114.0745.93136.14129.71139.94129.68194.86269.19198.52190.86223.97208.98334.37307.74303.3260.06303.48401.42589.4552.88540.74868.92
71.3653.3557.1326.9625.274.490.4614254576.7973.974.129.278.1320.5938.0374149.55306.99263.32342.82264.55371.31376.55191.43
00000001.073.836.06020.651.835.866.28.261.932.262.281.871.591.881.871.362.21
92.6328.4828.695.911.232.145.256.267.948.8810.549.0416.2928.1231.1929.0929.0733.7636.5125.5528.5329.3926.2636.3240.2540.89
163.9981.8385.8232.8726.516.635.7121.3236.7759.9587.3385.0121.0639.2245.1755.8775.36109.69188.31334.81293.72373.8292.69409.5418.16234.53
0.170.090.10.090.040.050.140.150.180.190.280.350.220.230.270.260.410.420.490.590.60.780.880.960.961.1
0.170.080.10.130.070.090.260.30.370.430.550.710.760.850.941.11.321.391.521.671.691.862.042.272.322.44
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of GC Biopharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand GC Biopharma's financial health and stability.

Assets

GC Biopharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that GC Biopharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of GC Biopharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into GC Biopharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (B)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-49.16-87.07-8.4730.414.847.26.7829.1334.7944.3648.8780.52113.9857.655.6172.0386.7995.6965.1556.7134.25-11.2989.27136.9569.42
3.063.1431.711.571.554.077.758.3510.4710.4216.7510.8813.0415.6618.4223.5228.4331.0736.7240.1346.6748.7955.965.1
00000-2.51-4.517.470.190.04-1.271.540000000000000
24.77-3.35-1.453.82-30.19-21.465.05-18.9-29.63-16.9-784.71-85.07-55.04-43.87-78.98-72.83-89.1-126.34-75.73-93.81-58.72-99.11-45.6-62.56
-21.8482.086.45-32.7-6.543.274.95-2.1713.62-2.74-0.758.4945.1939.2623.3618.2219.2810.2328.3740.1733.8463.63-2.98-21.2847.2
0000000000002.831.762.1804.514.864.595.836.557.069.7313.5519.38
00000000000037.5731.9320.4915.8919.5230.6443.2815.0115.3717.798.9818.8737.35
-43.17-5.2-0.473.24-30.32-11.9416.3423.2727.3235.22-20.73112.0184.9754.8650.7629.6956.7645.24-1.7457.8814.4140.2935.97125.98119.15
-152-2,341-606-427-1,481-3,669-6,584-21,583-37,833-74,437-63,449-19,689-30,757-55,025-73,453-90,641-70,719-135,638-98,667-55,570-65,036-147,617-101,395-123,539-94,690
69.834.93-0.5-0.27-12.6221.14-9.09-19.54-36.01-54.25-49.55-70.94-86.82-38.63-90.35-70.4-163.427.84-111.0914.83-86.08-177.9129.68-132.08-205.26
69.987.270.10.15-11.1424.8-2.52.041.8320.1813.9-51.25-56.0616.4-16.920.24-92.7143.47-12.4270.4-21.04-30.29131.08-8.54-110.57
0000000000000000000000000
-16.344.012.1524.76-0.53-4.81-1.09-9.087.8523.0394.6-21.22-43.19-31.6345.12-35.47112.19-21.9116.0763.916.5369.1182.38-16.09-20.57
0-0.01023.19-0.010-15.613.065.444.350.2514.5363.1330.49093.5211.899.3114.98-0.5400035.9541.93
-24.660.430.6245.17-3.92-9.466.64-5.979.0810.876.02-30.459.2-15.3530.0245.97109.44-27.62110.5648.18-4.51140.8180.99-41.27-2.48
-8.33-3.57-1.53-2.78-3.39-4.6523.350.050.12-10-9.99-14.910.753.170.380.810.1100.020.15-5.7184.0711.33-42.610.15
00000000-4,329-6,583-8,842-8,846-11,484-17,379-15,472-12,892-14,738-15,028-20,500-15,330-15,326-12,378-12,719-18,511-23,985
1.990.16-0.3648.13-46.87-0.2713.89-2.240.4-8.235.7410.627.230.9-9.624.984.3525.73-0.82114.06-74.341.83133.83-46.23-80.69
-43,323-7,540-1,0782,808-31,802-15,6129,7511,689-10,511-39,213-84,17892,31754,216-170-22,696-60,952-13,956-90,394-100,4092,309-50,626-107,326-65,4212,440.2624,464.07
0000000000000000000000000

GC Biopharma stock margins

The GC Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GC Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GC Biopharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the GC Biopharma's sales revenue. A higher gross margin percentage indicates that the GC Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the GC Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the GC Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GC Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GC Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GC Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

GC Biopharma Margin History

GC Biopharma Gross marginGC Biopharma Profit marginGC Biopharma EBIT marginGC Biopharma Profit margin
2026e29.79 %6 %3.33 %
2025e29.79 %5.25 %2.31 %
2024e29.79 %3.73 %0.44 %
202329.79 %2.12 %-1.64 %
202234 %4.75 %3.82 %
202133.85 %4.79 %8.01 %
202029.29 %3.34 %5.39 %
201927.42 %3.07 %-0.27 %
201825.91 %3.76 %2.58 %
201728.48 %7.01 %4.13 %
201629.39 %6.55 %5.26 %
201532.35 %8.75 %9.06 %
201431.84 %9.94 %8.61 %
201330.95 %8.87 %7.89 %
201231.24 %9.16 %6.61 %
201133.71 %11.12 %7.21 %
201040.6 %19.3 %14.34 %
200941.94 %18.56 %12.52 %
200839.57 %13.16 %9.47 %
200740.79 %13.21 %10.03 %
200640.64 %13.54 %8.59 %
200536.09 %9.12 %7.82 %
200433.2 %3.54 %4.78 %

GC Biopharma Stock Sales Revenue, EBIT, Earnings per Share

The GC Biopharma earnings per share therefore indicates how much revenue GC Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue GC Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates GC Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of GC Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GC Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

GC Biopharma Revenue, EBIT and net profit per share

DateGC Biopharma Sales per ShareGC Biopharma EBIT per shareGC Biopharma Earnings per Share
2026e180,282.89 undefined0 undefined5,998.52 undefined
2025e165,915.69 undefined0 undefined3,831.27 undefined
2024e153,696.7 undefined0 undefined682.56 undefined
2023142,523.28 undefined3,017.23 undefined-2,333.42 undefined
2022149,941.8 undefined7,120.16 undefined5,734.87 undefined
2021134,741.22 undefined6,454.08 undefined10,795.57 undefined
2020136,737.73 undefined4,568.45 undefined7,368.09 undefined
2019123,374.27 undefined3,789.27 undefined-330.73 undefined
2018121,352.55 undefined4,559.18 undefined3,129.91 undefined
2017117,083.27 undefined8,208.91 undefined4,840.64 undefined
201699,825.34 undefined6,537.67 undefined5,247.5 undefined
201587,317.66 undefined7,640 undefined7,913.92 undefined
201481,277.25 undefined8,080.5 undefined6,995.42 undefined
201380,742.55 undefined7,164.36 undefined6,369.64 undefined
201273,797.63 undefined6,759.64 undefined4,876.64 undefined
201169,810.18 undefined7,762.36 undefined5,033.36 undefined
201079,304.9 undefined15,304.8 undefined11,369.1 undefined
200964,320.8 undefined11,938.8 undefined8,052.4 undefined
200851,609.7 undefined6,793.2 undefined4,887.3 undefined
200744,229.9 undefined5,844.6 undefined4,435.7 undefined
200645,013.11 undefined6,096 undefined3,865.89 undefined
200541,374 undefined3,773.78 undefined3,237 undefined
200423,663 undefined837.33 undefined1,130.33 undefined

GC Biopharma business model

GC Biopharma is one of the most popular companies on Eulerpool.com.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

GC Biopharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

GC Biopharma historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

GC Biopharma shares outstanding

The number of shares was GC Biopharma in 2023 — This indicates how many shares 11.413 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue GC Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates GC Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of GC Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GC Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

GC Biopharma stock splits

In GC Biopharma's history, there have been no stock splits.

GC Biopharma dividend history and estimates

In 2023, GC Biopharma paid a dividend amounting to 1,500 KRW. Dividend means that GC Biopharma distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for GC Biopharma provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify GC Biopharma’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating GC Biopharma's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

GC Biopharma Dividend History

DateGC Biopharma Dividend
2026e1,555.91 undefined
2025e1,554.78 undefined
2024e1,556.14 undefined
20231,500 undefined
20221,750 undefined
20212,000 undefined
20201,500 undefined
20191,000 undefined
20181,000 undefined
20171,250 undefined
20161,250 undefined
20151,750 undefined
20141,250 undefined
20131,250 undefined
20121,190.48 undefined
20111,428.57 undefined
20101,666.67 undefined
20091,190.48 undefined
2008952.38 undefined
2007952.38 undefined
2006714.29 undefined
2005476.19 undefined

GC Biopharma dividend payout ratio

In 2023, GC Biopharma had a payout ratio of 23.13%. The payout ratio indicates the percentage of the company's profits that GC Biopharma distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for GC Biopharma represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for GC Biopharma could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate GC Biopharma's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

GC Biopharma Payout Ratio History

DateGC Biopharma Payout ratio
2026e24.36 %
2025e25.9 %
2024e24.06 %
202323.13 %
202230.52 %
202118.53 %
202020.36 %
2019-302.37 %
201831.95 %
201725.82 %
201623.82 %
201522.11 %
201417.87 %
201319.62 %
201224.41 %
201128.38 %
201014.66 %
200914.78 %
200819.49 %
200721.47 %
200618.48 %
200514.71 %
200423.13 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for GC Biopharma.

GC Biopharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024766.53 -608  (-179.32 %)2024 Q2
3/31/2024-199.48 -2,218  (-1,011.92 %)2024 Q1
12/31/2023-437.84 -1,740  (-297.41 %)2023 Q4
9/30/20232,450.19 1,220  (-50.21 %)2023 Q3
6/30/20231,357.4 155  (-88.58 %)2023 Q2
3/31/2023-76.9 -1,967  (-2,457.82 %)2023 Q1
12/31/2022505.16 755  (49.46 %)2022 Q4
9/30/20224,126.36 3,287  (-20.34 %)2022 Q3
6/30/2022635.29 1,133  (78.34 %)2022 Q2
3/31/2022905.97 559.85  (-38.2 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the GC Biopharma stock

Eulerpool World ESG Rating (EESG©)

18/ 100

🌱 Environment

40

👫 Social

2

🏛️ Governance

12

Environment

Scope 1 - Direct Emissions
12,374
Scope 2 - Indirect emissions from purchased energy
54,480
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
66,854
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

GC Biopharma shareholders

%
Name
Stocks
Change
Date
51.26093 % Green Cross Holdings5,850,48203/31/2024
10.29689 % National Pension Service1,175,19834,4119/27/2024
1.37101 % The Vanguard Group, Inc.156,475-9,9459/30/2024
0.69186 % Norges Bank Investment Management (NBIM)78,96345,9866/30/2024
0.61824 % BlackRock Institutional Trust Company, N.A.70,5612429/30/2024
0.60627 % Dimensional Fund Advisors, L.P.69,19509/30/2024
0.57980 % Heo (Il Seop)66,17303/31/2024
0.45904 % Samsung Asset Management Co., Ltd.52,391-2,7909/30/2024
0.44606 % Mokam Science Janghak Foundation50,91003/31/2024
0.40361 % Mirae Asset Global Investments Co., Ltd.46,065659/30/2024
1
2
3
4
5
...
10

GC Biopharma Executives and Management Board

Mr. Yil Seop Huh(68)
GC Biopharma Chairman (since 2004)
Compensation 1.08 B
Mr. Eun Cheol Huh(51)
GC Biopharma President, Chief Executive Officer, Director (since 2010)
Compensation 958 M
Mr. Yeong Tae Lee(65)
GC Biopharma Internal Auditor
Mr. Yin Gyu Lee(50)
GC Biopharma Head of Factory of Hwasun Factory
Mr. Hyeong Jun Park(49)
GC Biopharma Head of Factory of Eumseong Factory
1
2

Most common questions regarding GC Biopharma

What is the P/E ratio of GC Biopharma 2024?

The GC Biopharma P/E ratio is 190.61.

What is the P/S ratio of GC Biopharma 2024?

The GC Biopharma P/S ratio is 0.85.

What is the Quality Investing of GC Biopharma?

The Quality Investing for GC Biopharma is 1/10.

What is the revenue of GC Biopharma 2024?

The expected GC Biopharma revenue is 1.75 T KRW.

How high is the profit of GC Biopharma 2024?

The expected GC Biopharma profit is 7.79 B KRW.

What is the business model of GC Biopharma

No history available for GC Biopharma.

What is the GC Biopharma dividend?

GC Biopharma pays a dividend of 1,750 KRW distributed over payouts per year.

How often does GC Biopharma pay dividends?

The dividend cannot currently be calculated for GC Biopharma or the company does not pay out a dividend.

What is the GC Biopharma ISIN?

The ISIN of GC Biopharma is KR7006280002.

What is the GC Biopharma ticker?

The ticker of GC Biopharma is 006280.KS.

How much dividend does GC Biopharma pay?

Over the past 12 months, GC Biopharma paid a dividend of 1,500 KRW . This corresponds to a dividend yield of about 1.15 %. For the coming 12 months, GC Biopharma is expected to pay a dividend of 1,554.78 KRW.

What is the dividend yield of GC Biopharma?

The current dividend yield of GC Biopharma is 1.15 %.

When does GC Biopharma pay dividends?

GC Biopharma pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of GC Biopharma?

GC Biopharma paid dividends every year for the past 22 years.

What is the dividend of GC Biopharma?

For the upcoming 12 months, dividends amounting to 1,554.78 KRW are expected. This corresponds to a dividend yield of 1.2 %.

In which sector is GC Biopharma located?

GC Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von GC Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GC Biopharma from 5/1/2024 amounting to 1,500 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did GC Biopharma pay the last dividend?

The last dividend was paid out on 5/1/2024.

What was the dividend of GC Biopharma in the year 2023?

In the year 2023, GC Biopharma distributed 1,750 KRW as dividends.

In which currency does GC Biopharma pay out the dividend?

The dividends of GC Biopharma are distributed in KRW.

All fundamentals about GC Biopharma

Our stock analysis for GC Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GC Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.